A team led by Prof. Jan Konvalinka has developed a compound that destroys the yeast Cryptococcus neoformans – a fungus which is life-threatening for people with weakened immune systems – in laboratory settings.

Scientists at IOCB Prague created an eco-friendly method to recycle rare earths like neodymium from magnets, offering a sustainable alternative to mining and boosting EU & US raw material security.

Dr. Tomáš Pluskal, winner of the Neuron Award, and his team created DreaMS, a machine learning model that accelerates molecule analysis. Published in Nature Biotechnology.

A team at IOCB Prague revealed a novel phase where liquids flip rapidly between metal and nonmetal states. The theory, based on advanced modeling, was featured in Nature Communications.

The scientific team of Dr. Pavel Majer from the IOCB of the CAS has developed a new substance with the potential to treat the autoimmune disease alopecia areata, which is manifested by hair loss.

Roman and Anton Bushuiev joined experts from 14 institutes in MassSpecGym, a project to benchmark AI methods for discovering natural molecules from MS, aiding drug development, ecology, and space research.

Dr. Tomáš Pluskal has been accepted into the prestigious ‘Young Investigator Programme’ of the EMBO and has also secured the ERC grant.

An important step in countering antibiotic resistance has been made by researchers from IOCB Prague, the Institute of Microbiology and the Institute of Biotechnology of the CAS.

IOCB Prague opened its new branch in Boston, USA on October 18, 2024. The move puts the institute in proximity to scientific institutions, such as Harvard University, MIT, and Boston Medical Center.

Researchers from IOCB Prague are furthering the understanding of how medicines work and what it takes to develop their most effective variants.